<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052879</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0220 - TORONTO</org_study_id>
    <nct_id>NCT05052879</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Toronto Association in the Treatment of Erectile Dysfunction and Premature Ejaculation</brief_title>
  <official_title>National, Multicenter, Randomized, Double-blind, Double-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Toronto Association in the Treatment of Erectile Dysfunction and Premature Ejaculation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Toronto association in&#xD;
      the treatment of both sexual dysfunction: erectile dysfunction and premature ejaculation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2022</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with treatment response after 4 weeks of treatment.</measure>
    <time_frame>4 weeks</time_frame>
    <description>The treatment response will be based on the participant's questionnaire answer after the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with treatment response after 8 weeks of treatment.</measure>
    <time_frame>8 weeks</time_frame>
    <description>The treatment response will be based on the participant's questionnaire answer after the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>103 days</time_frame>
    <description>Incidence and severity of adverse events recorded during the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Erectile Dysfunction</condition>
  <condition>Premature Ejaculation</condition>
  <arm_group>
    <arm_group_label>TORONTO 20 + 30/60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:&#xD;
1 tablet of Toronto association, oral;&#xD;
1 tablet of tadalafil placebo, oral.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TADALAFIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:&#xD;
1 tablet of tadalafil , oral;&#xD;
1 tablet of Toronto association placebo, oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toronto association</intervention_name>
    <description>Toronto association coated tablet, 20 mg + 30 mg or 20 mg + 60 mg, oral, 2 hours before the sexual intercourse.</description>
    <arm_group_label>TORONTO 20 + 30/60</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Tadalafil coated tablet, 20 mg, oral, 2 hours before the sexual intercourse.</description>
    <arm_group_label>TADALAFIL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tadalafil placebo</intervention_name>
    <description>Tadalafil placebo coated tablet, oral, 2 hours before the sexual intercourse.</description>
    <arm_group_label>TORONTO 20 + 30/60</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Toronto association placebo</intervention_name>
    <description>Toronto association placebo coated tablet, oral, 2 hours before the sexual intercourse.</description>
    <arm_group_label>TADALAFIL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to confirm voluntary participation and agree to all trial purposes by signing&#xD;
             and dating the informed consent forms;&#xD;
&#xD;
          -  Male participants, with age greater than or equal to 18 years;&#xD;
&#xD;
          -  Heterosexual, sexually active participants in a stable and monogamous relationship for&#xD;
             at least 6 months before screening and who plan to maintain this relationship&#xD;
             throughout the study period;&#xD;
&#xD;
          -  Participants with erectile dysfunction, in stable and effective treatment with PDE-5&#xD;
             inhibitors;&#xD;
&#xD;
          -  Participants diagnosed with premature ejaculation;&#xD;
&#xD;
          -  Participants with IELT ≤ 2 minutes;&#xD;
&#xD;
          -  Participants with score ≥ 25 points in the erectile function questionnaire;&#xD;
&#xD;
          -  Participants (or partners) who use at least one contraceptive method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinical and laboratory findings that, in the judgment of the investigator, may&#xD;
             interfere with the safety of research participants;&#xD;
&#xD;
          -  Participation in a clinical trial in the year prior to this study;&#xD;
&#xD;
          -  Known hypersensitivity to any of the formula compounds;&#xD;
&#xD;
          -  Participants with cardiovascular disease for whom sexual activity is inadvisable&#xD;
&#xD;
          -  History or current experience of surgical interventions or radiotherapy in the pelvic&#xD;
             region, neurological conditions, trauma or infections that are associated with the&#xD;
             symptoms premature ejaculation;&#xD;
&#xD;
          -  Diagnosis of other diseases or conditions in the urinary tract;&#xD;
&#xD;
          -  Participants with conditions that may predispose them to priapism;&#xD;
&#xD;
          -  History of severe psychiatric or psychosocial disorders;&#xD;
&#xD;
          -  Participant whose partner has clinically important sexual dysfunctions.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arthur M Kummer, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ncfarma.com.br</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile dysfunction</keyword>
  <keyword>Premature Ejaculation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Premature Ejaculation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

